WHOOP Joins $34.5M Bid to Quantify Aging
Wearables company WHOOP has entered a $34.5 million government-backed project with ARPA-H to quantify the process of aging. The initiative aims to develop new digital biomarkers to measure health and aging, highlighting the growing intersection of consumer tech and advanced medical research.
The project, named THRIVE (Transforming Health: Reclaiming Intrinsic Vitality for Everyone), is a collaboration led by Stanford University's Dr. Michael Snyder. Key partners include the Buck Institute for Research on Aging and the Methuselah Foundation, with implementation support from organizations like the YMCA and OpenCures. At the core of the initiative is the development of the first FDA-grade "Intrinsic Capacity" (IC) score. This concept, defined by the World Health Organization, represents the combination of an individual's physical and mental abilities. The goal is to create a predictive model that can forecast major health outcomes up to 20 years in advance. WHOOP's specific contribution will be to supply continuous, real-world physiological data from its wearable devices. This data, tracking metrics like sleep patterns and cardiovascular strain, will be integrated with health surveys, functional assessments, and blood-based biomarkers to build the comprehensive IC score. This initiative is part of a larger ARPA-H program called PROSPR (PROactive Solutions for Prolonging Resilience). The broader PROSPR program is investing up to $144 million across seven research teams to develop tools and therapies that extend "healthspan," the number of years people live in good health. The ultimate aim of the THRIVE project is to translate the complex data into an accessible at-home assessment. The coalition is working towards an ambitious target price of under $100 for this assessment, aiming to make proactive health monitoring widely available. This project represents a significant shift from treating diseases after they emerge to proactively preserving health. By creating a reliable surrogate endpoint for age-related decline, the PROSPR platform could dramatically accelerate clinical trials for therapies targeting the aging process itself.
